Zealand Pharma

Board/Management Information • Apr 16, 2014

Copenhagen, 2014-04-16 22:20 CEST (GLOBE NEWSWIRE) --

Company Announcement
No. 8/2014

Copenhagen, 16 April 2014 – Zealand Pharma A/S (Zealand) (NASDAQ OMX
Copenhagen: ZEAL), announces that Jens Peter Stenvang, Senior Application
Specialist, has been elected as the third employee elected member of the
company’s Board of Directors. Jens Peter Stenvang, (1954) is a qualified
laboratory technician and he has been employed at Zealand since 2010.

Jens Peter Stenvang’s appointment is for a four-year period and takes effect
following Zealand’s Annual General Meeting to be held on Tuesday, 29 April
2014, where he will replace Hanne Heidenheim Bak following completion of her
term on the Board. The two other employee elected members of the Board of
Directors have also been appointed for four-year periods, which will complete
at the company’s Annual General Meeting in 2016.

As first, second, third and fourth substitute employee representatives, the
following have been elected: Søren Vitfell Keller, Head of Legal Affairs, Hanne
Heidenheim Bak, Senior Director, Maria Juul Kolding, Manager of Documentation
and Helle Haxgart, Accountant.

                                  ***

For further information, please contact:

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology
company based in Copenhagen, Denmark. Zealand specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company’s focus lies in the field of cardio-metabolic diseases,
diabetes and obesity in particular, and its lead drug invention is
lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi
for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as
Lyxumia®) is approved in several countries globally, including Europe and
Japan. In the U.S., an NDA is planned to be submitted in 2015, after completion
of the ELIXA Cardiovascular outcome study. In February 2014, Sanofi started the
pivotal Phase 3 clinical program for the Lantus®/Lyxumia® combination product
(LixiLan).

Zealand has a partnering strategy for the development and commercialization of
its products and, in addition to the license agreement with Sanofi in Type 2
diabetes, the company has partnerships with Boehringer Ingelheim in
diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in
chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: zealandpharma.com

Follow us on Twitter @ZealandPharma